An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2018
At a glance
- Drugs NEO-PV 01 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed; Poly ICLC
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Neon Therapeutics
- 01 Oct 2018 According to a Neon Therapeutics media release, data from the trial will be presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting.
- 31 Aug 2018 Biomarkers information updated
- 06 Aug 2018 According to a Neon Therapeutics media release, 52-week data is expected in the second half of 2019.